Upon receiving the appropriate activating signal, natural killer T (NKT) cells live up to their name, releasing a torrent of molecules that trigger the protective immune response necessary to eliminate pathogens or even thwart tumor growth.
These cells represent a promising clinical tool, as demonstrated in a recent clinical trial in which lung cancer patients received NKT-stimulating injections of dendritic cells that had been pretreated with á-galactosylceramide (á-GalCer)1. Some 60% of treated patients exhibited a striking seven-fold improvement in their median survival time relative to their untreated counterparts. “The effects are superior to other molecular-targeted cancer drugs,” says Masaru Taniguchi of the RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, whose team participated in this study. “However, this therapy is not applicable to two-thirds of patients because of their limited number of NKT cells.”
To solve this problem, Taniguchi teamed up with RCAI colleague Haruhiko Koseki to develop a method for generating transplantable NKTs2. They derived these from induced pluripotent stem cells (iPSCs), embryonic-like cells that are typically generated via virus-mediated delivery of ‘reprogramming genes’ into skin cells. However, NKT maturation involves a complex genomic rearrangement event, making them difficult to derive from conventional iPSCs. As such, Taniguchi and Koseki devised a novel approach for generating mouse iPSCs from existing NKTs, which have already undergone this rearrangement. They used these iPSCs to generate large numbers of new NKTs in vitro.
Their method efficiently produced mature NKTs, which rapidly established a stable population within the liver upon transplantation into mice. To the researchers’ pleasant surprise, these new NKTs displayed typical activation behavior in response to á-GalCer-treated dendritic cells and proved capable of coordinating an effective immune response. “In general, cells generated from in vitro culture die quickly in vivo or are killed by host immune cells … however, this was not the case here,” says Taniguchi. “We detected iPSC-derived NKT cells with adjuvant activity and tumor-eradicating effects two weeks after cell transfer.”
Taniguchi, Koseki and colleagues are now keen to begin working with human cells. This transition will involve many new challenges, but the researchers see great clinical potential in their approach—particularly in the US, where the Food and Drug Administration has approved development of cell-based therapies. “NKT cell-targeted adjuvant cell therapy is applicable [to] any type of cancer patient, because it can overcome [their] immunodeficient status and enhances antitumor responses,” says Taniguchi. “At present, the delivery of patient dendritic cells is the main limiting factor.”The corresponding author for this highlight is based at the Laboratory for Immune Regulation, RIKEN Research Center for Allergy and Immunology
Associated linksLink to article
2. 2.Watarai, H., Fujii, S., Yamada, D., Rybouchkin, A., Sakata, S., Nagata, Y., Iida-Kobayashi, M., Sekine-Kondo, E., Shimizu, K., Shozaki, Y. et al. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. The Journal of Clinical Investigation 120, 2610–2618 (2010).
Further reports about: > Allergy > Creating > Immunology > Koseki > NKT > NKT cells > RCAI > RIKEN > T cells > Taniguchi > cancer drug > dendritic cells > human cell > immune cell > immune response > induced pluripotent stem > induced pluripotent stem cell > lung cancer > natural killer T > pluripotent stem cells > skin cell > stem cells
Enduring cold temperatures alters fat cell epigenetics
19.04.2018 | University of Tokyo
Full of hot air and proud of it
18.04.2018 | University of Pittsburgh
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.
The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...
Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.
Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...
In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...
In an article that appears in the journal “Review of Modern Physics”, researchers at the Laboratory for Attosecond Physics (LAP) assess the current state of the field of ultrafast physics and consider its implications for future technologies.
Physicists can now control light in both time and space with hitherto unimagined precision. This is particularly true for the ability to generate ultrashort...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
19.04.2018 | Materials Sciences
19.04.2018 | Physics and Astronomy
19.04.2018 | Physics and Astronomy